News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Study achieves primary endpoint of radiographic progression-free survival
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Subscribe To Our Newsletter & Stay Updated
